Active, not recruitingPhase 3NCT05481151
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Studying Polycythemia vera
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PharmaEssentia
- Principal Investigator
- Ole Zagrijtschuk, MD, PhDPharmaEssentia Corporation
- Intervention
- P1101 (Ropeginterferon alfa-2b-njft)(drug)
- Enrollment
- 111 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (23)
- Baptist MD Anderson, Jacksonville, Florida, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- University of Kansas Medical Center, Westwood, Kansas, United States
- Mercy Health, Paducah, Kentucky, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders), Bethesda, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Astera HealthCare, East Brunswick, New Jersey, United States
- Mount Sinai, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- East Carolina University, Greenville, North Carolina, United States
- Wake Forest Baptist Medical Center, High Point, North Carolina, United States
- University of Tennessee Health Science Center, Memphis, Tennessee, United States
- MD Anderson, Houston, Texas, United States
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05481151 on ClinicalTrials.govOther trials for Polycythemia vera
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)MPN Research Foundation
- RECRUITINGPHASE2NCT07232290Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE2NCT06985147A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Disc Medicine, Inc
- RECRUITINGNCT06743035Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyiOMEDICO AG
- RECRUITINGNCT06752941LOW-PV ContinuationFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE3NCT06093672Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraItalfarmaco
- RECRUITINGPHASE1NCT06752746A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraMabwell (Shanghai) Bioscience Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06033586Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraProtagonist Therapeutics, Inc.